Nivolumab
- Generic Name
- Nivolumab
- Brand Names
- Opdivo, Opdualag
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 946414-94-4
- Unique Ingredient Identifier
- 31YO63LBSN
- Background
Nivolumab is a fully human IgG4 antibody targeting the immune checkpoint programmed death receptor-1 (PD-1). This antibody was produced entirely in mice and grafted onto human kappa and IgG4 Fc region with the mutation S228P for additional stability and reduced variability. It was developed by Bristol Myers Squibb.
...
- Indication
Nivolumab is indicated to treat unresectable or metastatic melanoma, melanoma as adjuvant treatment, resectable or metastatic non-small cell lung cancer, small cell lung cancer, advanced renal cell carcinoma, classical Hodgkin lymphoma, squamous cell carcinoma of the head and neck, urothelial carcinoma, microsatellite instability-high or mismatch repair defi...
- Associated Conditions
- Advanced Esophageal Adenocarcinoma, Advanced Gastric Adenocarcinoma, Advanced Gastric Carcinoma, Advanced Gastroesophageal Junction Adenocarcinoma, Advanced Renal Cell Carcinoma, Classical Hodgkin's Lymphoma, Completely resected Stage IIB melanoma, Completely resected Stage III melanoma, Completely resected Stage IV melanoma, Hepatocellular Carcinoma, Locally Advanced Hepatocellular Carcinoma, Locally Advanced Non-Small Cell Lung Cancer, Melanoma, Metastatic Colorectal Cancer (CRC), Metastatic Esophageal Adenocarcinoma, Metastatic Esophageal Squamous Cell Carcinoma, Metastatic Gastric Adenocarcinoma, Metastatic Gastric Cancers, Metastatic Gastroesophageal Junction Adenocarcinoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Renal Cell Carcinoma ( mRCC), Metastatic Squamous Cell Carcinoma of the Head and Neck (HNSCC), Metastatic Urothelial Carcinoma (UC), Mismatch Repair-deficient (dMMR) Metastatic Colorectal Cancer (CRC), Muscle-invasive Urothelial Carcinoma, Poor Risk Advanced Renal Cell Cancer, Recurrent Non-small Cell Lung Cancer, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma, Relapsed or Refractory Classical Hodgkin's Lymphoma, Resectable Non-small Cell Lung Cancer, Stage IIB Melanoma, Stage IIC Melanoma, Unresectable Esophageal Squamous Cell Carcinoma, Unresectable Locally Advanced Urothelial Cancer, Unresectable Melanoma, Urothelial Carcinoma, Completely resected Stage IIC melanoma, Intermediate risk Advanced Renal Cell Cancer, Locally advanced Urothelial Carcinoma, Metastatic Microsatellite Instability High Colorectal Cancer, Metastatic Mismatch Repair Deficient Colorectal Cancer, Metastatic gastroesphageal juntion adenocarcinoma, Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN), Relapsed Classical Hodgkin's Lymphoma, Residual Esophageal Cancer, Residual Gastroesophageal Junction Cancer, Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable advanced, recurrent or metastatic oesophageal squamous cell carcinoma, Unresectable, advanced Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, metastatic Esophageal Squamous Cell Carcinoma (ESCC), Unresectable, recurrent Esophageal Squamous Cell Carcinoma (ESCC)
- Associated Therapies
- Complete Surgical Resection, Neoadjuvant Therapies
Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2023-02-06
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 618
- Registration Number
- NCT05714371
- Locations
- 🇺🇸
Novartis Pharmaceuticals, East Hanover, New Jersey, United States
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
- Conditions
- Interventions
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Hackensack Meridian Health
- Target Recruit Count
- 108
- Registration Number
- NCT05715229
- Locations
- 🇺🇸
John Theurer Cancer Center, Hackensack Meridian Health, Hackensack, New Jersey, United States
🇺🇸Lombardi Comprehensive Cancer Center, Georgetown University, Washington, District of Columbia, United States
🇺🇸Jersey Shore University Medical Center, Neptune, New Jersey, United States
EON: A Single-arm Phase II Study of Etigilimab (OMP-313M32) in Combination With Checkpoint Inhibition (Nivolumab) in Patients With Platinum-resistant, Recurrent Epithelial Ovarian Cancer
- First Posted Date
- 2023-02-06
- Last Posted Date
- 2024-07-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT05715216
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase II Study of Nivolumab in Combination With Relatlimab in Patients With Active Melanoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 30
- Registration Number
- NCT05704647
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Pilot Study of Nivolumab w/Ipilimumab or Relatlimab in Surgically Resectable Melanoma Brain Metastases
- Conditions
- Interventions
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-12-09
- Target Recruit Count
- 1
- Registration Number
- NCT05704933
- Locations
- 🇺🇸
M.D. Anderson Cancer Center, Houston, Texas, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
Nivolumab Plus Lenvatinib Against Anaplastic Thyroid Cancer (NAVIGATION)
- Conditions
- Interventions
- First Posted Date
- 2023-01-25
- Last Posted Date
- 2024-03-21
- Lead Sponsor
- National Cancer Center Hospital East
- Target Recruit Count
- 51
- Registration Number
- NCT05696548
- Locations
- 🇯🇵
Nippon Medical School Hospital, Tokyo, Japan
🇯🇵Osaka Metropolitan University Hospital, Osaka, Japan
🇯🇵Aichi Cancer Center, Nagoya, Aichi, Japan
DUMAS: Neo-Adjuvant Immunotherapy for Pancoast Tumors
- Conditions
- Interventions
- First Posted Date
- 2023-01-13
- Last Posted Date
- 2024-08-19
- Lead Sponsor
- Fundación GECP
- Target Recruit Count
- 40
- Registration Number
- NCT05684276
- Locations
- 🇪🇸
Hospital Universitari Vall d' Hebron, Barcelona, Spain
🇪🇸Hospital Universitario Jerez De La Frontera, Jerez De La Frontera, Cádiz, Spain
🇪🇸Fundació Althaïa, Manresa, Spain
Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
- Conditions
- Interventions
- First Posted Date
- 2023-01-12
- Last Posted Date
- 2024-12-11
- Target Recruit Count
- 20
- Registration Number
- NCT05681780
- Locations
- 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma
- Conditions
- Clinical Stage III Gastric Cancer AJCC v8Advanced Esophageal AdenocarcinomaClinical Stage III Esophageal Adenocarcinoma AJCC v8Unresectable Esophageal AdenocarcinomaUnresectable Gastroesophageal Junction AdenocarcinomaAdvanced Gastric AdenocarcinomaAdvanced Gastroesophageal Junction AdenocarcinomaClinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Esophageal Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- Alliance for Clinical Trials in Oncology
- Target Recruit Count
- 382
- Registration Number
- NCT05677490
- Locations
- 🇺🇸
CARTI Cancer Center, Little Rock, Arkansas, United States
🇺🇸Sutter Auburn Faith Hospital, Auburn, California, United States
🇺🇸Sutter Cancer Centers Radiation Oncology Services-Auburn, Auburn, California, United States
Study of XL092 + Nivolumab vs Sunitinib in Subjects With Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2023-01-10
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Exelixis
- Target Recruit Count
- 291
- Registration Number
- NCT05678673
- Locations
- 🇺🇸
Exelixis Clinical Site #164, Newport Beach, California, United States
🇺🇸Exelixis Clinical Site #162, San Francisco, California, United States
🇺🇸Exelixis Clinical Site #163, Aurora, Colorado, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.